Karen Bhatt

Karen Bhatt investigates the intersection of germline cancer predisposition variants and pharmacogenomics, examining how cancer risk genes also influence drug metabolism and toxicity. Her research has identified how BRCA2, Lynch syndrome genes, and other cancer susceptibility genes modulate chemosensitivity beyond their roles in carcinogenesis. She contributes to Clinical Pharmacogenomics Implementation Consortium (CPIC) guidelines that inform clinical implementation of pharmacogenomics testing. Her work advances the integration of cancer genetic counseling and pharmacogenomics into comprehensive personalized oncology care.